About: A 2-year comparative open label randomized study of efficacy and safety of etanercept and infliximab in patients with ankylosing spondylitis

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: A 2-year comparative open label randomized study of efficacy and safety of etanercept and infliximab in patients with ankylosing spondylitis Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 23 October 2009

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) наукова стаття, опублікована в жовтні 2009 (uk) im Oktober 2009 veröffentlichter wissenschaftlicher Artikel (de) scientific article published on 23 October 2009 (en) artículu científicu espublizáu n'ochobre de 2009 (ast)
publication date	wds:Q84772075-7EC266D2-A1B4-46FD-89ED-506AC8FA1305
publication date	2009-10-23 00:00:00Z (xsd:dateTime)
exact match	wds:Q84772075-D2243B3C-4C1E-40CD-9BFF-E85262537B77
exact match	https://scigraph.springernature.com/pub.10.1007/s00296-009-1157-3
cites work	wds:Q84772075-0EABDA7F-B21A-4AE2-9CA4-7A72BE7CFFCD wds:Q84772075-13D45745-0790-4CC3-B6D9-E0662B4686B5 wds:Q84772075-15E5E571-B8D5-45E1-8EC4-6BF2ACFBE3E0 wds:Q84772075-16F3EFC2-8FAF-4C9C-91AB-769961AB3841 wds:Q84772075-23BB270B-4DE0-4F3C-B6EB-4A098059CB53 wds:Q84772075-2B196CA9-6804-4B98-8776-ACB975E752D1 wds:Q84772075-2F381D0B-11DB-4EE8-9DEF-3205B12CC2F7 wds:Q84772075-3D35E519-9471-4C7D-BBE5-250EA27FCDA4 wds:Q84772075-4C292DDB-2CD2-44E3-8497-22553DD12B42 wds:Q84772075-6582CA51-B003-483C-93C8-57C276115FDB wds:Q84772075-6AD6868D-E83A-474D-B89D-3875A69F2E9F wds:Q84772075-701D4B55-CD17-41C1-91BF-721AF06CA2A2 wds:Q84772075-77367484-03D5-415D-9627-B1C57426E981 wds:Q84772075-7AFF11E4-9C67-424D-9026-873D89A2FCBF wds:Q84772075-89752B5E-C79E-409B-9FA9-CF52CA3FF020 wds:Q84772075-D042D013-24C5-426C-AE6B-7D4DD81A278E wds:Q84772075-E800652E-3219-4951-83F5-F8D4DE7FEE03 wds:Q84772075-F0CA90C3-6F48-43A0-9EB4-6FB45A1E1A2C wds:Q84772075-FA967C57-2C8F-436E-BBA5-7579827C2AFF
cites work	Update on spondyloarthropathies Efficacy and safety of up to 192 weeks of etanercept therapy in patients with ankylosing spondylitis Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial Defining spinal mobility in ankylosing spondylitis (AS). The Bath AS Metrology Index. Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT) Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: an open, observational, extension study of a three-month, randomized, placebo-controlled trial Evaluation of ankylosing spondylitis spinal mobility measurements in the assessment of spinal involvement in psoriatic arthritis The benefit/risk profile of TNF-blocking agents: findings of a consensus panel Infliximab in combination with methotrexate in active ankylosing spondylitis: a clinical and imaging study Current evidence for the management of ankylosing spondylitis: a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis Long-term efficacy and safety of etanercept after readministration in patients with active ankylosing spondylitis Two year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitis Major reduction in spinal inflammation in patients with ankylosing spondylitis after treatment with infliximab: Results of a multicenter, randomized, double-blind, placebo-controlled magnetic resonance imaging study Cytokine gene polymorphisms relevant for the spondyloarthropathies
author name string	wds:Q84772075-9DFCBAAF-AD22-4407-B405-BB7F578AD91E wds:Q84772075-B59034CE-3368-47CF-8FC3-F4E43076A5B2 wds:Q84772075-D228BF89-5B08-429B-81BF-03091C80C43A
author name string	Alfonso Principato Maria Concetta Miceli Rosalia Impastato
rdfs:label	A 2-year comparative open label randomized study of efficacy and safety of etanercept and infliximab in patients with ankylosing spondylitis (en) A 2-year comparative open label randomized study of efficacy and safety of etanercept and infliximab in patients with ankylosing spondylitis (nl)
skos:prefLabel	A 2-year comparative open label randomized study of efficacy and safety of etanercept and infliximab in patients with ankylosing spondylitis (en) A 2-year comparative open label randomized study of efficacy and safety of etanercept and infliximab in patients with ankylosing spondylitis (nl)
name	A 2-year comparative open label randomized study of efficacy and safety of etanercept and infliximab in patients with ankylosing spondylitis (en) A 2-year comparative open label randomized study of efficacy and safety of etanercept and infliximab in patients with ankylosing spondylitis (nl)
author	wds:Q84772075-169EC0D7-5F04-400E-9E16-95E63D8BD2DA wds:Q84772075-2597EC02-1F0A-4093-97FA-CA7AC28EEFF8 wds:Q84772075-F8C392FD-AE65-40EC-91BD-61D0F74F3BA5 wds:Q84772075-FBFF63C4-DF32-436D-BAE4-67571AA37EEB
author	Francesco Ciccia Giovani Triolo Annarita Giardina Angelo Ferrante
title	wds:Q84772075-447541E2-3C58-43FD-B356-AFD77462B895
title	A 2-year comparative open label randomized study of efficacy and safety of etanercept and infliximab in patients with ankylosing spondylitis (en)
page(s)	wds:Q84772075-C7D00BA2-D45D-40E0-BC79-474DA7352029
page(s)	1437-1440
instance of	wds:Q84772075-3B8A5E99-5535-4D00-893B-27A9191C79A7
instance of	scholarly article
main subject	wds:Q84772075-9059E583-5136-4F6F-9B46-D9733CFED8A4
main subject	ankylosing spondylitis
PubMed ID	wds:Q84772075-5520DAD6-9F63-4EFB-AC80-57C6CBF8057D
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/19851772
PubMed ID	19851772
published in	wds:Q84772075-683D5237-AA61-4ACB-BEAF-B996A4926E97
published in	Rheumatology International
issue	wds:Q84772075-CF8B2EFB-04C0-449B-9DDE-D892352225E4
volume	wds:Q84772075-7AC286E6-E74F-416C-BF74-3D95F03D9727
issue	11
volume	30
DOI	wds:Q84772075-3AE13435-E185-4CAB-A6DA-A19C0E57D1D6
DOI	http://dx.doi.org/10.1007/S00296-009-1157-3
DOI	10.1007/S00296-009-1157-3
Dimensions Publication ID	wds:Q84772075-563EAFEA-4F81-4DC2-8062-354DF6C46D9D
Dimensions Publication ID	1027538745
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q84772075
is cites work of	Different roles of TNF inhibitors in acute anterior uveitis associated with ankylosing spondylitis: state of the art. Comparable long-term efficacy, as assessed by patient-reported outcomes, safety and pharmacokinetics, of CT-P13 and reference infliximab in patients with ankylosing spondylitis: 54-week results from the randomized, parallel-group PLANETAS study Treatment of ankylosing spondylitis with TNF blockers: a meta-analysis Infliximab: 12 years of experience Etanercept: a review of its use in autoimmune inflammatory diseases Efficacy of anti-tumor necrosis factor therapy for extra-articular manifestations in patients with ankylosing spondylitis: a meta-analysis TNF-alpha inhibitors for ankylosing spondylitis [German Society for Rheumatology S3 guidelines on axial spondyloarthritis including Bechterew's disease and early forms: 8.4 Pharmaceutical therapy, 8.5 Evaluation of therapy success of pharmaceutical measures]. Efficacy and safety of biological and targeted-synthetic DMARDs: a systematic literature review informing the 2016 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 172 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software